A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)

Summary

This study is a single-center, double-blind, randomized controlled clinical trial with placebo as the control, aiming to evaluate the effectiveness of spermidine in preventing radiation-induced xerostomia during radiotherapy for head and neck tumors (including nasopharyngeal carcinoma).

Timeline

Start

2025-06-25

Primary completion

2026-06-08

Completion

2026-06-08

Publications

• Min Y, Gao K, Liu Y, Dai L, Peng X. Oral Spermidine Supplementation Preserves Submandibular Gland Function After Radiotherapy: Mechanistic Insights and Use in a Phase II Randomized Clinical Trial. MedComm (2020). 2026 Jul 15;7(8):e70862. doi: 10.1002/mco2.70862. eCollection 2026 Aug.

Drugs

Indications